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INTRODUCTION {#psyg12481-sec-0005}
============

In recent years, there have been several studies on the prevention of dementia onset and cognitive decline through physical activity interventions,[1](#psyg12481-bib-0001){ref-type="ref"} cognitive training interventions,[2](#psyg12481-bib-0002){ref-type="ref"} supplementary interventions[3](#psyg12481-bib-0003){ref-type="ref"} and reduction of behavioural psychological symptoms of dementia (BPSD) by providing cognitive behaviour therapy,[4](#psyg12481-bib-0004){ref-type="ref"} caregivers\' education[5](#psyg12481-bib-0005){ref-type="ref"} and care services.[6](#psyg12481-bib-0006){ref-type="ref"} Non‐pharmacological approaches have received much attention, and aromatherapy is considered a non‐pharmacological therapy. In our previous study,[7](#psyg12481-bib-0007){ref-type="ref"} we reported a therapeutic improvement effect of aromas spread using a diffuser, which used rosemary camphor and lemon essential oil in the morning and true lavender and sweet orange essential oils in the evening, on cognitive function in patients with dementia. Moreover, other studies have reported that aromatherapy had effects on agitation and emotional functioning,[8](#psyg12481-bib-0008){ref-type="ref"} and improved the symptoms of sleep disturbance in patients with dementia.[9](#psyg12481-bib-0009){ref-type="ref"} Therefore, aromatherapy is expected to improve both cognitive symptoms and BPSD.

Some patients with dementia exhibit olfactory disorders, and there are several reports on olfactory disorders, particularly in patients with Alzheimer\'s disease (AD) and those with dementia with Lewy bodies (DLB).[10](#psyg12481-bib-0010){ref-type="ref"}, [11](#psyg12481-bib-0011){ref-type="ref"} Furthermore, it has been reported that patients with mild cognitive impairment (MCI), which is a pre‐dementia state, exhibited olfactory disorders[12](#psyg12481-bib-0012){ref-type="ref"}, [13](#psyg12481-bib-0013){ref-type="ref"}, [14](#psyg12481-bib-0014){ref-type="ref"} and that MCI patients with severe olfactory disorder exhibited poor memory performance.[15](#psyg12481-bib-0015){ref-type="ref"} In addition, it has been reported that amyloid ß, phosphorylated tau and alpha synuclein, which are proteins associated with the pathogenesis of AD or DLB, were deposited in olfactory‐related areas.[16](#psyg12481-bib-0016){ref-type="ref"}, [17](#psyg12481-bib-0017){ref-type="ref"}, [18](#psyg12481-bib-0018){ref-type="ref"}, [19](#psyg12481-bib-0019){ref-type="ref"}, [20](#psyg12481-bib-0020){ref-type="ref"} Therefore, it is considered that the decreases in olfactory test scores are caused by neurodegeneration and cognitive disorder. In an animal study, the ability of olfactory precursor cells to generate new neurons was found to decrease with ageing,[21](#psyg12481-bib-0021){ref-type="ref"} and in an autopsy study, mitral cells in the olfactory bulb were shown to decrease with age.[22](#psyg12481-bib-0022){ref-type="ref"} Therefore, ageing is also considered to be involved in the decline of olfactory function. Previous studies have reported that olfactory training performed in patients exposed twice daily to four intense odours (phenyl ethyl alcohol, eucalyptol, citronellal and eugenol) increased the olfactory bulb volume estimated using magnetic resonance imaging (MRI) in healthy participants (age range: 19--43 years)[23](#psyg12481-bib-0023){ref-type="ref"} and olfactory function in approximately 30% of patients with olfactory loss (age range: 23--79 years).[24](#psyg12481-bib-0024){ref-type="ref"} Although the findings in patients with dementia remain unknown, it is speculated that stimulating the sense of smell with aromatherapy may enhance olfactory function.

According to the results of our previous research,[7](#psyg12481-bib-0007){ref-type="ref"} because the mean score of a cognitive function test deteriorated after discontinuing aromatherapy in test subjects, we believe that it is important to continue this type of therapy. Therefore, we considered that bathing, which is familiar to Japanese individuals and easy to incorporate into everyday life, would be a good method. In this study, as a primary outcome, we evaluated the effects of bath salt with aromas of true lavender and sweet orange essential oils, which had been confirmed effect on cognitive function in our previous research,[7](#psyg12481-bib-0007){ref-type="ref"} on cognitive function. As a secondary outcome, we evaluated the effects of aroma oil as a bath salt on olfactory function and sleep quality. The aim of the present research was to establish a new aromatherapy method that could improve cognitive function, olfactory function and sleep quality.

METHODS {#psyg12481-sec-0006}
=======

Subjects {#psyg12481-sec-0007}
--------

Between February 2016 and April 2018, 49 subjects were recruited from Shinsei Hospital (Kurayoshi, Japan) outpatient clinic. The inclusion criteria were AD that met the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, fifth edition[25](#psyg12481-bib-0025){ref-type="ref"} or MCI that met Petersen\'s diagnostic criteria.[26](#psyg12481-bib-0026){ref-type="ref"}, [27](#psyg12481-bib-0027){ref-type="ref"} The exclusion criteria were a diagnosis of allergic dermatitis and/or of olfactory disturbance and/or cutis symptoms \> grade 2 in hand and foot syndrome. Finally, 43 subjects participated in the study.

The design of this study was approved by the ethics committee of Tottori University (approval number: 1508B012) and followed the Declaration of Helsinki. The study was registered in the UMIN Clinical Trials Registry (UMIN000019044). The research protocol was explained to the patients and guardians who provided informed consent for participation.

Procedures {#psyg12481-sec-0008}
----------

This was a randomised controlled trial. The schedule of the study is shown in Figure [1](#psyg12481-fig-0001){ref-type="fig"}. The first examination was conducted after obtaining consent. Following a 4‐week observation period, the second examination was performed. We carried out block randomisation and the patients were randomly assigned to use 0.1%, 0.5% or 1% aroma bath salts, as presented in Table [1](#psyg12481-tbl-0001){ref-type="table"}. The aroma oil added to the bath salt was a 2:1 blend of true lavender and sweet orange, which had been confirmed to improve cognitive function in our previous research.[7](#psyg12481-bib-0007){ref-type="ref"} The intervention period was 24 weeks. Bathing was performed after 18:00 hours. One bag of 1% or 0.5% or 0.1% of the aroma oil/bath salt in the volumes shown in Table [1](#psyg12481-tbl-0001){ref-type="table"} was added to the bath, and the subjects were asked to stay in the bathroom for ≥10 min. The daily usage of bath salt was recorded in a diary by the patient or guardian. The third examination was performed 12 weeks after the initiation of intervention, and the fourth examination was performed 24 weeks after the initiation of intervention. Following a 4‐week observation period, the fifth examination was performed. Assessments included: the Touch Panel‐type Dementia Assessment Scale (TDAS) (Nihon Kohden Corporation, Tokyo, Japan)[28](#psyg12481-bib-0028){ref-type="ref"}; the Odor Stick Identification Test for Japanese (OSIT‐J)[29](#psyg12481-bib-0029){ref-type="ref"} (Daiichi Yakuhin Sangyo Co., Ltd., Tokyo, Japan) and the Japanese version of the Pittsburgh Sleep Quality Index (PSQI‐J).[30](#psyg12481-bib-0030){ref-type="ref"}, [31](#psyg12481-bib-0031){ref-type="ref"}

![Schedule of this study.](PSYG-20-163-g001){#psyg12481-fig-0001}

###### 

Components of the bath salt

  Component                      Daily dose (g)
  ------------------------------ ----------------
  0.1% perfume (total: 30 g)     
  Anhydrous sodium sulphate      18
  Sodium hydrogen carbonate      11.67
  Light anhydrous silicic acid   0.21
  Riboflavin                     0.09
  Aroma oil                      0.03
  0.5% perfume (total: 30 g)     
  Anhydrous sodium sulphate      18
  Sodium hydrogen carbonate      11.55
  Light anhydrous silicic acid   0.21
  Riboflavin                     0.09
  Aroma oil                      0.15
  1% perfume (total: 30 g)       
  Anhydrous sodium sulphate      18
  Sodium hydrogen carbonate      11.40
  Light anhydrous silicic acid   0.21
  Riboflavin                     0.09
  Aroma oil                      0.30

Cognitive function test {#psyg12481-sec-0009}
-----------------------

To assess cognitive function, we used the TDAS.[28](#psyg12481-bib-0028){ref-type="ref"} The TDAS is a modified version of the Alzheimer\'s disease Assessment Scale‐Cognitive Subscale (ADAS‐cog)[32](#psyg12481-bib-0032){ref-type="ref"}, [33](#psyg12481-bib-0033){ref-type="ref"} in which subjects enter their answers directly into a touch panel‐type computer following instructions. The nine examination items included 'word recognition', 'following a command', 'visual--spatial perception', 'accuracy of the order of a process', 'naming fingers', 'orientation', 'money calculation', 'object recognition' and 'clock time recognition'. Scores ranged from 0 (all correct answers) to 101 points (all incorrect answers). The validity and reliability of the TDAS has previously been tested and the results showed a significant association between the TDAS and ADAS‐cog.[28](#psyg12481-bib-0028){ref-type="ref"} Another study confirmed the results of performing the TDAS twice in patients with MCI.[34](#psyg12481-bib-0034){ref-type="ref"}

Olfactory test {#psyg12481-sec-0010}
--------------

We performed the OSIT‐J as an olfactory test.[29](#psyg12481-bib-0029){ref-type="ref"} The experimenter applied an odorous semisolid cream from an odour stick to a 2‐cm circle on a thin paraffin paper, folded the paper in half, rubbed it to grind the microcapsules and passed it to the patient. The patient then opened and sniffed the paper and chose one of six possible answers: four items plus 'detectable but not recognised' and 'no smell detected'. There were 12 kinds of smells familiar to Japanese (India ink, wood, perfume, menthol, Japanese orange, curry, cooking gas, rose, Japanese cypress, fermented beans/sweaty socks, condensed milk and roasted garlic). A score of 12 points indicated that the patient answered all questions correctly, and a score of 0 points indicated that the patient\'s answers were all incorrect. As for the validity and reliability of the OSIT‐J, a previous study showed a significant association with the OSIT‐J and cross‐cultural smell identification test and examined test--retest reliability.[29](#psyg12481-bib-0029){ref-type="ref"}

The validity and reliability of the OSIT‐J was previously tested, and the results showed a significant association between the OSIT‐J and the cross‐cultural smell identification test and determined test--retest reliability.[29](#psyg12481-bib-0029){ref-type="ref"}

Sleep questionnaire {#psyg12481-sec-0011}
-------------------

To assess sleep quality, we used the PSQI‐J.[30](#psyg12481-bib-0030){ref-type="ref"}, [31](#psyg12481-bib-0031){ref-type="ref"} The PSQI‐J is a self‐administered questionnaire consisting of 18 questions. The self‐rated items of the PSQI generate seven component scores (range of subscale scores, 0--3): sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medication and daytime dysfunction. The sum of these seven component scores yields one global score of subjective sleep quality (range, 0--21), with higher scores representing poorer subjective sleep quality. In a test of the validity and reliability of the PSQI‐J, a previous study showed that PSQI‐J scores were significantly higher in patients with primary insomnia and the PSQI‐J demonstrated a high degree of internal homogeneity.[31](#psyg12481-bib-0031){ref-type="ref"}

Statistical analysis {#psyg12481-sec-0012}
--------------------

The sample size was originally targeted to be 60 patients (20 in each arm) on the basis of feasibility considerations. However, because of difficulties in the recruitment process, the sample size was reduced to 43. In our previous study[7](#psyg12481-bib-0007){ref-type="ref"} that used the TDAS to examine the effect of aromatherapy on cognitive function, 17 patients with AD were studied. Therefore, we considered that the effect on cognitive function could be proven by including 20 patients in each group. We were unable to infer the effect size in the calculation of the sample size because of the lack of previous research that had evaluated the effect of aroma oil bath salt on cognitive symptoms. Therefore, we did not perform a power analysis in this study.

SPSS statistical software (version 25, IBM Japan, Tokyo, Japan) was used for statistical analyses. The Shapiro--Wilk test was performed to assess the normal distributions of the data. Differences in the baseline demographics and background characteristics of the subjects were assessed by using one‐way analysis of variance, the Kruskal--Wallis test or the Chi‐squared test. The fluctuation of each test result before and after use of the aroma bath salt in each group was evaluated by one‐way repeated measures analysis of variance or the Friedman test. Mean changes from pre‐intervention for each measured outcome were compared between groups by using one‐way analysis of variance or the Kruskal--Wallis test. In the multiple comparisons, we used the Tukey method or Bonferroni correction. Pearson\'s correlation coefficient or Spearman\'s correlation coefficient was used to evaluate the correlations between TDAS scores and the results of the other tests. All statistical significance tests were two‐sided, and an alpha‐level of 0.05 was considered as indicative of statistical significance.

RESULTS {#psyg12481-sec-0013}
=======

Subjects and baseline characteristics {#psyg12481-sec-0014}
-------------------------------------

Figure [2](#psyg12481-fig-0002){ref-type="fig"} shows the patient flow in this study. Tests were performed on 43 patients. The patients were assigned to 0.1%, 0.5% or 1% aroma bath salt groups, and 35 patients underwent all tests. As a breakdown, there were 13 patients in the 0.1% aroma bath salt use group (three with AD, 10 with MCI), 11 patients in the 0.5% aroma bath salt use group (two with AD, nine with MCI) and 11 patients in the 1% aroma bath salt use group (five with AD, six with MCI). The characteristics of the patients are summarised in Table [2](#psyg12481-tbl-0002){ref-type="table"}. The groups did not differ in terms of age, sex, TDAS scores, OSIT‐J scores or PSQI‐J scores. A survey of bathing salt usage days from a self‐reported diary, showed that no patients used bath salts for less than two‐thirds of the 24‐week intervention period.

![Flow chart of the subjects of this study.](PSYG-20-163-g002){#psyg12481-fig-0002}

###### 

Baseline demographic characteristics of the subjects

                     Bath salt containing an aroma component                                  
  ----------------- ----------------------------------------- --------------- --------------- -------
  Number (*n*)                         13                           11              11           ‐
  Age, years                       76 (75--81)                 78 (75.5--81)   82 (78.5--84)   0.181
  Sex (M:F)                            9:4                          4:7             4:7        0.171
  Type of disease                                                                             
  AD, *n*/%                          3/23.1                       2/18.2          5/45.5         ‐
  MCI, *n*/%                         10/76.9                      9/81.8          6/54.5         ‐
  TDAS                              6 (1--17)                   5 (4.5--11)    12 (9--18.5)    0.185
  OSIT‐J                            3 (1--6)                   5 (4.5--6.5)     2 (1--3.5)     0.051
  PSQI‐J                            3 (2--5)                    4 (1--5.5)       3 (2--3)      0.626

Data presented as median (interquartile range).

AD, Alzheimer\'s disease; MCI, mild cognitive impairment; TDAS, Touch Panel‐type Dementia Assessment Scale; OSIT‐J, Odour Stick Identification Test for Japanese; PSOI‐J, Japanese version of the Pittsburgh Sleep Quality Index.

Changes in the TDAS, OSIT‐J and PSQI‐J scores {#psyg12481-sec-0015}
---------------------------------------------

The results of the TDAS, OSIT‐J and PSQI‐J scores are shown in Figures [3](#psyg12481-fig-0003){ref-type="fig"}a--i. There were no significant changes in the TDAS, OSIT‐J and PSQI‐J scores during the study period in all groups. Moreover, there were no significant differences in the changes in the TDAS, OSIT‐J and PSQI‐J scores from pre‐intervention (week 4) to intermediate intervention (week 16) or post‐intervention (week 28) between the groups (Table [3](#psyg12481-tbl-0003){ref-type="table"}). When the cut‐off point of OSIT‐J was set to ≤7.5 points in reference to the previous research,[12](#psyg12481-bib-0012){ref-type="ref"} 31 (88.6%) patients had olfactory disorders at baseline. When the cut‐off point of PSQI‐J was set to ≥5.5 points in reference to the previous research,[31](#psyg12481-bib-0031){ref-type="ref"} six (17.1%) patients showed declines in subjective sleep quality from baseline values.

![Changes in scores of the TDAS (a--c), OSIT‐J (d--f) and PSQI‐J (g--i). All data are presented as the mean ± standard error. In all groups, changes in the TDAS, OSIT‐J and PSQI‐J scores did not differ significantly throughout the study period. TDAS, Touch Panel‐type Dementia Assessment Scale; OSIT‐J, Odour Stick Identification Test for Japanese; PSOI‐J, Japanese version of the Pittsburgh Sleep Quality Index.](PSYG-20-163-g003){#psyg12481-fig-0003}

###### 

Change in the TDAS, OSIT‐J and PSQI‐J scores from pre‐intervention

                    0.1% group   0.5% group   1% group     *P*‐value
  ----------------- ------------ ------------ ------------ -----------
  TDAS                                                     
  Week 16--Week 4   1.7 (2.0)    1.5 (1.1)    1.1 (0.9)    0.962
  Week 28--Week 4   0.2 (2.5)    2.3 (1.9)    1.6 (1.4)    0.727
  OSIT‐J                                                   
  Week 16--Week 4   −0.3 (0.5)   −0.5 (0.4)   −0.5 (0.5)   0.906
  Week 28--Week 4   −0.4 (0.5)   −1.5 (0.5)   −0.7 (0.5)   0.353
  PSQI‐J                                                   
  Week 16--Week 4   0 (0.4)      0.2 (0.3)    0.1 (0.3)    0.874
  Week 28--Week 4   −0.2 (0.5)   −0.4 (0.2)   0.1 (0.3)    0.712

Data presented as mean (standard error).

TDAS, Touch Panel‐type Dementia Assessment Scale; OSIT‐J, Odour Stick Identification Test for Japanese; PSOI‐J, Japanese version of the Pittsburgh Sleep Quality Index.

Correlations between the TDAS and other outcomes {#psyg12481-sec-0016}
------------------------------------------------

Table [4](#psyg12481-tbl-0004){ref-type="table"} shows the results of correlation analysis between the changes in the TDAS scores and other test results from pre‐intervention (week 4) to intermediate intervention (week 16) or post‐intervention (week 28). In the correlation analysis of the pre‐intervention to intermediate intervention results, the 0.1% aroma bath salt group showed a significant association with sleep latency and sleep disturbances, which are sub‐items of the PSQI‐J (*r* = 0.660, *r* = 0.618, respectively). In contrast, in the 0.5% aroma bath salt group and 1% aroma bath salt group, no significant correlation was observed between the TDAS scores and other test results. In the correlation analysis of the pre‐intervention to post‐intervention results, there were no significant correlations observed between the TDAS scores and the other test results in all groups.

###### 

Correlation between TDAS and other tests prior to and after the intervention

                               Change from week 4 to week 16                    Change from week 4 to week 28                              
  ---------------------- ----- ------------------------------------------------ ------------------------------- -------- -------- -------- --------
  OSIT‐J                 *r*   0.259                                            0.832                           0.030    0.276    −0.190   0.152
  PSQI‐J component                                                                                                                         
  Sleep quality          *r*   −0.211                                           −0.075                          −0.350   0.237    0.139    −0.149
  Sleep latency          *r*   0.660[\*](#psyg12481-note-0006){ref-type="fn"}   −0.102                          −0.437   0.462    −0.169   0.068
  Sleep duration         *r*   0.536                                            −0.413                          −0.562   0.054    ‐        −0.439
  Sleep efficiency       *r*   ‐                                                ‐                               ‐        0.325    ‐        ‐
  Sleep disturbances     *r*   0.618[\*](#psyg12481-note-0006){ref-type="fn"}   0.204                           0.301    −0.090   −0.100   0.301
  Sleep medication use   *r*   0.310                                            ‐                               0.502    0.497    ‐        ‐
  Daytime dysfunction    *r*   −0.115                                           ‐                               0.402    −0.122   −0.187   0.401
  Total score            *r*   0.529                                            −0.119                          −0.316   0.318    −0.091   −0.091

*P* \< 0.05.

'--' means that correlation analysis could not be performed because there was no change prior to or after the intervention.

*r*, correlation; TDAS, Touch Panel‐type Dementia Assessment Scale; OSIT‐J, Odour Stick Identification Test for Japanese; PSOI‐J, Japanese version of the Pittsburgh Sleep Quality Index.

Safety {#psyg12481-sec-0017}
------

There were no serious adverse events in any group. Minor adverse events, including complaints of redness and itching of the skin, were reported: one patient with skin itching in the 0.1% aroma bath salt group, two patients with skin redness in the 0.5% aroma bath salt group and one patient with skin itching in the 1% aroma bath salt group.

DISCUSSION {#psyg12481-sec-0018}
==========

The study results showed there were no improvements in cognitive function, olfactory function or sleep quality associated with the use of 0.1%, 0.5% or 1% aroma bath salt during a 24‐week period. In addition, no differences in the effects on cognitive function, olfactory function and sleep quality due to the differences in aroma oil concentrations were observed.

Our previous study[7](#psyg12481-bib-0007){ref-type="ref"} reported that aromatherapy provided by diffusing different odours in the morning and evening in patients with dementia improved cognitive function evaluated by TDAS. Although the mechanism has not been elucidated yet, we speculated that stimulation of the sense of smell was projected to the cerebral limbic system and activated those areas, including the hippocampus and amygdala. In the present study, we tried to stimulate the sense of smell by inhaling odorous molecules that spread from the bath waters throughout the bathroom and examined the effect on cognitive function, but the expected effect was not obtained. The reason for these different results could be that, unlike in the previous research, only the blended smells of true lavender and sweet orange were used, the implemented method and time of the aromatherapy were different, and the study included MCI patients with relatively mild cognitive decline.

It is well known that olfactory sensory neurons are replaced; that is, new neurons are made continuously to replace the old ones.[35](#psyg12481-bib-0035){ref-type="ref"} Furthermore, sensory input to the olfactory bulb plays a key role in the survival of newly generated granule cells.[36](#psyg12481-bib-0036){ref-type="ref"} Previous studies have reported that olfactory training with odorants have increased the olfactory bulb volume estimated by MRI in healthy participants[23](#psyg12481-bib-0023){ref-type="ref"} and olfactory function in patients with olfactory loss.[24](#psyg12481-bib-0024){ref-type="ref"} Therefore, we speculated that olfactory function may be enhanced by stimulating the sense of smell with aromatherapy, but when aromatherapy with bath salt was performed for elderly people with dementia in this study, there was no improvement in olfactory function. Therefore, although results may differ depending on the methodology, in the method of this study we observed no improvement in the olfactory function of elderly dementia patients with olfactory dysfunction due to neurodegeneration.

It has been reported that inhalation aromatherapy using essential oils, such as linalool, santalol, cedrol and piperonal, that are also contained in essential oils blended with true lavender and sweet oranges improved symptoms of sleep disturbance in the elderly with dementia.[9](#psyg12481-bib-0009){ref-type="ref"} Therefore, aromatherapy may have the effect of improving sleep quality. In addition, according to the results of animal experiments, the concentration of amyloid β protein in brain interstitial fluid, which is one of the causal proteins in AD, decreased approximately 25% during sleep relative to that after awakening.[37](#psyg12481-bib-0037){ref-type="ref"} Additionally, a human study found that the amount of amyloid β protein in cerebrospinal fluid changed daily by increasing during wakefulness and decreasing during sleep.[38](#psyg12481-bib-0038){ref-type="ref"} Furthermore, in a longitudinal study in which non‐demented participants aged \>65 years were followed for 3 years, sleep inadequacy and increased daytime sleepiness were risk factors for dementia in older adults,[39](#psyg12481-bib-0039){ref-type="ref"} which suggested that dementia and sleep are closely related. Although the improvement in sleep quality could not be proved in this study, a significant correlation was found between the variation in the PSQI‐J sub‐item and the variation in the TDAS results during the intervention period in the 0.1% aroma bath salt use group. Although it is not possible to identify which, change in sleep or cognitive function, preceded the other, the results of the previous research discussed above and odour components indicate that subjects whose sleep quality was improved by the use of aroma bath salts also tended to show improved cognitive function. However, similar results were not obtained in the 0.5% and 1% aroma bath salt use groups, and there was no correlation in the total PSQI‐J score in the 0.1% aroma bath salt use group. We think that it is necessary to increase the number of subjects and to evaluate outcomes longitudinally whether or not these positive results can be confirmed.

Several limitations of this study should be considered. The first is the small number of subjects. Recruitment was difficult because people who bathed at a day‐service facility or had a hot spring at their home (as is unique to the area) could not use the bath salts. As the target number of cases was not reached, we believe it would be worthwhile to increase the number of subjects and to analyse further. The second limitation is the concentration of the aroma bath salts. Because the subjects used the bath salts at home, the sizes of the bathrooms varied, and the density of the vaporised aroma components in the bathroom might have been different.

In this study, we could not find any effect on cognitive function, olfactory function or sleep quality by using aroma bath salt. A previous descriptive analysis of randomised clinical trials showed that results were different because of differences in the aroma therapeutic method used.[40](#psyg12481-bib-0040){ref-type="ref"} Therefore, to obtain the effects of aromatherapy, we thought that it was necessary to consider the kinds of odour, the method of operation, the exposure time and selection of appropriate subjects. However, despite our main negative finding, our results suggest that there is room for a further investigation to evaluate the relationship between improvement in sleep quality and improved cognitive function by using aroma bath salts. There are few existing reports on the effects of aromatherapy on cognitive function, olfactory function and sleep quality for patients with dementia. Although we did not obtain the expected results in this study, in future it will be necessary to collect further data and to examine the mechanism of the effect at the molecular level.
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